Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization.
Identifieur interne : 000D78 ( Ncbi/Merge ); précédent : 000D77; suivant : 000D79Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization.
Auteurs : James D. Marks [États-Unis]Source :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2004.
English descriptors
- KwdEn :
- Animals, Antibodies, Monoclonal (immunology), Antibodies, Monoclonal (pharmacology), Antibody Specificity, Antigen-Antibody Reactions (physiology), Botulinum Toxins, Type A (immunology), Botulinum Toxins, Type A (pharmacology), Botulism (prevention & control), Dose-Response Relationship, Drug, Drug Synergism, Enzyme-Linked Immunosorbent Assay (methods), Epitope Mapping, Humans, Lethal Dose 50, Neuromuscular Agents (immunology), Neuromuscular Agents (pharmacology), Neurotoxins (metabolism), Neutralization Tests (methods).
- MESH :
- chemical , immunology : Antibodies, Monoclonal, Botulinum Toxins, Type A, Neuromuscular Agents.
- chemical , metabolism : Neurotoxins.
- chemical , pharmacology : Antibodies, Monoclonal, Botulinum Toxins, Type A, Neuromuscular Agents.
- methods : Enzyme-Linked Immunosorbent Assay, Neutralization Tests.
- physiology : Antigen-Antibody Reactions.
- prevention & control : Botulism.
- Animals, Antibody Specificity, Dose-Response Relationship, Drug, Drug Synergism, Epitope Mapping, Humans, Lethal Dose 50.
Abstract
Monoclonal antibodies (mAbs) have been developed that bind to the toxin binding domain (H(C)) of botulinum toxin type A. These mAbs recognize with high affinity nonoverlapping epitopes on native toxin. The potency of a combination of three of the mAbs is almost 100 times greater than that reported for human polyclonal botulinum immune globulin. Potency appears to result largely from a marked increase in binding affinity for toxin that results when antibodies are combined. Precise epitope, or even domain recognized, seems to be of much less importance. The very high affinity required for toxin neutralization suggests why single mAbs that potently neutralize toxin have not been reported. Such affinities are not typically generated by the immune response.
DOI: 10.1002/mds.20023
PubMed: 15027061
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003506
- to stream PubMed, to step Curation: 003506
- to stream PubMed, to step Checkpoint: 003504
Links to Exploration step
pubmed:15027061Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization.</title><author><name sortKey="Marks, James D" sort="Marks, James D" uniqKey="Marks J" first="James D" last="Marks">James D. Marks</name><affiliation wicri:level="1"><nlm:affiliation>Department of Anesthesia and Pharmaceutical Chemistry, University of California, San Francisco General Hospital, San Francisco, California 94110, USA. marksj@anesthesia.ucsf.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Anesthesia and Pharmaceutical Chemistry, University of California, San Francisco General Hospital, San Francisco, California 94110</wicri:regionArea><wicri:noRegion>California 94110</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:15027061</idno><idno type="pmid">15027061</idno><idno type="doi">10.1002/mds.20023</idno><idno type="wicri:Area/PubMed/Corpus">003506</idno><idno type="wicri:Area/PubMed/Curation">003506</idno><idno type="wicri:Area/PubMed/Checkpoint">003504</idno><idno type="wicri:Area/Ncbi/Merge">000D78</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization.</title><author><name sortKey="Marks, James D" sort="Marks, James D" uniqKey="Marks J" first="James D" last="Marks">James D. Marks</name><affiliation wicri:level="1"><nlm:affiliation>Department of Anesthesia and Pharmaceutical Chemistry, University of California, San Francisco General Hospital, San Francisco, California 94110, USA. marksj@anesthesia.ucsf.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Anesthesia and Pharmaceutical Chemistry, University of California, San Francisco General Hospital, San Francisco, California 94110</wicri:regionArea><wicri:noRegion>California 94110</wicri:noRegion></affiliation></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Monoclonal (immunology)</term><term>Antibodies, Monoclonal (pharmacology)</term><term>Antibody Specificity</term><term>Antigen-Antibody Reactions (physiology)</term><term>Botulinum Toxins, Type A (immunology)</term><term>Botulinum Toxins, Type A (pharmacology)</term><term>Botulism (prevention & control)</term><term>Dose-Response Relationship, Drug</term><term>Drug Synergism</term><term>Enzyme-Linked Immunosorbent Assay (methods)</term><term>Epitope Mapping</term><term>Humans</term><term>Lethal Dose 50</term><term>Neuromuscular Agents (immunology)</term><term>Neuromuscular Agents (pharmacology)</term><term>Neurotoxins (metabolism)</term><term>Neutralization Tests (methods)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Botulinum Toxins, Type A</term><term>Neuromuscular Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Neurotoxins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Botulinum Toxins, Type A</term><term>Neuromuscular Agents</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Enzyme-Linked Immunosorbent Assay</term><term>Neutralization Tests</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Antigen-Antibody Reactions</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Botulism</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Antibody Specificity</term><term>Dose-Response Relationship, Drug</term><term>Drug Synergism</term><term>Epitope Mapping</term><term>Humans</term><term>Lethal Dose 50</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Monoclonal antibodies (mAbs) have been developed that bind to the toxin binding domain (H(C)) of botulinum toxin type A. These mAbs recognize with high affinity nonoverlapping epitopes on native toxin. The potency of a combination of three of the mAbs is almost 100 times greater than that reported for human polyclonal botulinum immune globulin. Potency appears to result largely from a marked increase in binding affinity for toxin that results when antibodies are combined. Precise epitope, or even domain recognized, seems to be of much less importance. The very high affinity required for toxin neutralization suggests why single mAbs that potently neutralize toxin have not been reported. Such affinities are not typically generated by the immune response.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">15027061</PMID><DateCreated><Year>2004</Year><Month>03</Month><Day>17</Day></DateCreated><DateCompleted><Year>2004</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2010</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>19 Suppl 8</Volume><PubDate><Year>2004</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization.</ArticleTitle><Pagination><MedlinePgn>S101-8</MedlinePgn></Pagination><Abstract><AbstractText>Monoclonal antibodies (mAbs) have been developed that bind to the toxin binding domain (H(C)) of botulinum toxin type A. These mAbs recognize with high affinity nonoverlapping epitopes on native toxin. The potency of a combination of three of the mAbs is almost 100 times greater than that reported for human polyclonal botulinum immune globulin. Potency appears to result largely from a marked increase in binding affinity for toxin that results when antibodies are combined. Precise epitope, or even domain recognized, seems to be of much less importance. The very high affinity required for toxin neutralization suggests why single mAbs that potently neutralize toxin have not been reported. Such affinities are not typically generated by the immune response.</AbstractText><CopyrightInformation>Copyright 2004 Movement Disorder Society</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marks</LastName><ForeName>James D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Pharmaceutical Chemistry, University of California, San Francisco General Hospital, San Francisco, California 94110, USA. marksj@anesthesia.ucsf.edu</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 AI53389-01</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AI056493</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009465">Neuromuscular Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009498">Neurotoxins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.69</RegistryNumber><NameOfSubstance UI="D019274">Botulinum Toxins, Type A</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000911">Antibodies, Monoclonal</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000918">Antibody Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000937">Antigen-Antibody Reactions</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019274">Botulinum Toxins, Type A</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001906">Botulism</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000517">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004357">Drug Synergism</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004797">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018604">Epitope Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007928">Lethal Dose 50</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009465">Neuromuscular Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000276">immunology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009498">Neurotoxins</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009500">Neutralization Tests</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>33</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>3</Month><Day>18</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>6</Month><Day>16</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>3</Month><Day>18</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15027061</ArticleId><ArticleId IdType="doi">10.1002/mds.20023</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country></list><tree><country name="États-Unis"><noRegion><name sortKey="Marks, James D" sort="Marks, James D" uniqKey="Marks J" first="James D" last="Marks">James D. Marks</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D78 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000D78 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:15027061
|texte= Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:15027061" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |